Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

November 10, 2025

SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases

SanegeneBio has formed a worldwide research and licensing partnership with Eli Lilly and Company to develop RNAi [RNA interference] candidates for metabolic diseases.

SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases